The Official News & Technical Journal Of The International Society For Pharmacoeconomics And Outcomes Research
ISPOR 7th Annual International Meeting – BEST EVER

Stephen L. Priori, Director, ISPOR Publications
 
ISPOR 7th Annual International Meeting
Dedicated to the Memory of: John M. Eisenberg, MD, M.B.A.
(1946-2002)
As many of you know, this past spring saw the passing of one of the great leaders in our field. John Eisenberg, who was the director of the Agency for Health Care Research and Quality, died in March at the age of 55. Dr. Eisenberg was an extraordinary educator, researcher, administrator, and leader, who touched all of our lives, and represented the best in our field. His career was dedicated to ensuring that health care is based on a strong foundation of research and that the services provided reflect the needs and perspectives of patients. In his memory and in recognition of his soaring spirit, ISPOR dedicated this year's Annual Meeting to John Eisenberg.
 
Held at the Hyatt Regency Crystal City, Arlington, Virginia, USA, the ISPOR Annual International Meeting was once again successful. A record 1200 attendees from 31 different countries attended this year’s meeting.
 

Sunday Night, after a full day of pre-meeting activities, the ISPOR Student Network ended the day with the Student Ice Breaker Reception. With over 200 students registered for the meeting, attendance was high as games and door prizes helped ‘break the ice’ when greeting new student attendees.
 

AMCP Early Session: (l-r) Laurie Beth Burke RPh, MPH,
Peter M. Penna PharmD, Dell Mather PharmD,
and Peter Neumann ScD

Monday, May 20, 2002
The day began with the Early Bird Forum at 7 am. The morning’s session, AMCP Format For Formulary Submissions: Who Is Using Them, Who Will Be Evaluating Them, And What Regulatory Concerns Do They Raise, was moderated by Dell Mather PharmD, Senior Director, Pharmacotherapy Assessment & Policy, Prime Therapeutics, Inc, St. Paul, MN, USA, with speakers Peter M. Penna, PharmD, President, PM Penna LLC, Seattle, Washington, USA and AMCP Officer and Laurie Beth Burke RPh, MPH, Chief, Regulatory Review Branch FDA, CDER, DDMAC, Rockville, MD, USA. The panel discussed how this guidance is being used, who will be evaluating it, and possible regulatory concerns about its use.
 

Peter Neuman ScD
At 8am, Peter Neumann ScD, ISPOR Annual Meeting Program Chair and Assistant Professor of Policy & Decision Sciences, Harvard School of Public Health, Boston, MA, USA, welcomed all meeting attendees. After which, Eva Lydick PhD, ISPOR 2001-2002 President and Director of Epidemiology, AstraZeneca, Wilmington, DE, USA delivered the Presidential Address and announced the 2002 ISPOR Research Excellence Awardees.

The recipient of the 2002 ISPOR Research Excellence Award for Methodology Excellence was Bernie O’Brien, BA, MSC, PhD, Professor, McMaster University, Hamilton, ON, Canada. The recipient of the 2002 ISPOR Research Excellencce Award for Practical Application Excellence was David W. Baker, MD, MPH, Associate Professor, Case Western Reserve University, Cleveland, Ohio. The first ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award was presented to John E. Ware, Jr., PhD, CEO, QualityMetric, Inc., Lincoln, RI, USA.
 

First Plenary Session Session: (l-r) Edwin Hedblom PharmD,
Deborah Zarin MD, Jerry Avorn MD, and Sandy Schwartz MD

The First Plenary Session, Uses and Users of Outcomes Research: Meeting the Critical Needs?, moderated by Sandy Schwartz MD, Professor of Medicine and Health Management and Economics, University of Pennsylvania, Philadelphia, PA, USA, and presented by Jerome Avorn MD, Associate Professor, Harvard Medical School, Boston, MA, USA, with panelist Deborah Zarin MD, Director, Technology Assessment Program, Agency for Healthcare Research and Quality, US Department of Health & Human Services, Rockville, MD, USA, and Edwin Hedblom, PharmD, Chief Pharmacy Officer – AARP Pharmacy Division, UnitedHealth Group, Minnetonka, MN, USA. This session discussed how outcomes researchers have become more involved in cutting edge research, whether it be as the interface between clinical and marketing interests in drug companies, advisors regarding the use of patient reported outcomes (PRO) claims in marketing, or as experts regarding the use of pharmacoepidemiological and pharmacoeconomic data in public policy debates. The need to meet foreign standards for reimbursement approval was also discussed in this session as a new requirement for outcomes researchers, as well as educational and performance challenges for meeting these new opportunities and new roles for outcomes researchers.
After a 30-minute viewing of the first Poster Presentation Session, attendees chose one of 4 concurrent Podium Sessions covering cardiovascular disease, mental health, diabetes, and respiratory disorders.
 

Dell Mather PharmD Carolyn Clancy MD Bruce Crawford

Following a second viewing of the first Poster Presentations, perusal of the exhibit booths, and lunch, afternoon Issues Panels were held on topics: How Does Genomics Change Portfolio Management? led by Kevin Schulman MD, MBA, Director, Center for Clinical & Genetic Economics, Duke University, Durham, NC, USA; Standards of Evidence: What is Appropriate, was led by Bryan Luce PhD, MBA, Senior Research Leader & CEO, MEDTAP International, Bethesda, MD, USA; Should Meta-Analysis Only Include Clinical Trial Data, was led by Adrian Towse MA, Mphil, Director, Office of Health Economics, London, United Kingdom; and Who Will Develop New Drugs for Tuberculosis or Malaria, was led by Doris Rouse PhD, Director, Global Health, RTI International, Research Triangle Park, NC, USA.

After a brief break, attendees disbursed into Contributed Workshops Presentations along the five scientific tracks of methodology issues, health policy, quality of life, device and implementaion, and pracical issues.
Later in the day, the ISPOR Student Network and the Health Science Committee held Forums. At the Student Forum, the topic Careers in Academia Consuting, Government and Industry: A View form the Ivory Towers was presented by C. Daniel Mullins PhD, Associate Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA, and Dean Smith, PhD, Professor, University of Michigan, Ann Arbor, MI, USA. The Health Science Forum, was moderated by John Hutton BSc, Bphil, Chair, ISPOR Health Science Committee & Vice President, European Operations, MEDTAP International, London, UK. Discussions were conducted by Task Force Chairs: Michael Drummond PhD, HS Task Force On Use Of Pharmacoeconomics/ Health Economic Information In Healthcare Decision-Making and Director, University of York, Centre for Health Economics, Heslington York, UK, Francis Palumbo PhD, JD, HS Task Force On Code Of Ethics and Director, University of Maryland Center on Drugs & Public Policy Baltimore, MD, USA, Paul Kind Mphil, HS Task Force On Good Research Practices-Quality Of Life Studies and Senior Research Fellow, University of York, Centre for Health Economics Heslington, York, UK, Louis Morris PhD, HS Task Force On Good Research Practices–Prospective Studies and President, Louis A. Morris & Associates, Dix Hills, NY, USA; Milton Weinstein PhD, HS Task Force On Good Research Practices- Modeling and Professor, Health Policy & Management, Harvard School of Public Health Center for Risk Analysis, Boston, MA, USA, and Bradley Martin PharmD, Hs Task Force on Good Research Practices- Retrospective Database Studies and Associate Professor, University of Georgia, College of Pharmacy, Athens, GA, USA. Presentations included an update on ‘good research practices’, code of ethics, and use of pharmacoeconomic/health economic information in healthcare decision-making initiatives.

To end the first day of the 7th Annual International Meeting attendees were invited to the Exhibit Hall for and Exhibitors’ Open House, Poster Presentations, and Reception.

Tuesday, May 21, 2002
The second day of the 7th Annual International Meeting began with the second annual Breakfast with the Experts featuring Andrew H. Briggs DPhil, Health Economics Research Centre, Institute of Health Sciences, Oxford University, Oxford, UK, covering NICE (National Institute of Clinical Excellence); Marc Berger MD, Vice President, Outcomes Research & Management, Merck & Company, Inc., West Point, PA, USA, covering Outcomes Research in the Pharmaceutical Industry; Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA, discussing Quality of Life Research; and Milton Weinstein PhD, Professor, Health Policy & Management, Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA,
discussing Theoretical Issues in Cost-Effectiveness Analysis.

Following the breakfast, participants attended Podium Sessions on the four topics, methodology issues, health policy, cardiovascular diseases/disorders and cancerfollowed by a half-hour viewing of Exhibits and Poster Presentations.
 

Peter Davey MD, FRCP,
2002-2003 ISPOR president
Mark Nuijten MD

 

At 10 am, Peter Davey MD, FRCP, 2002-2003 ISPOR President & Head of Pharmacoeconomics, University of Dundee, Dundee, Scotland, UK, gave the Incoming Presidential Address. Following Dr. Davey’s address, Eva Lydick presented the ISPOR Board of Directors Awards and the ISPOR Distinguished Service Awards.
The Second Plenary Session titled The Rise Of Risk Management was moderated by Peter Neumann ScD, ISPOR Annual Meeting Program Chair and Assistant Professor of Policy & Decision Sciences, Harvard School of Public Health, Boston, MA, USA, and Lou Morris PhD; Plenary Session Chair and Founder & President, Louis A. Morris & Associates, Inc, Dix Hills, NY, USA. Speakers were John D. Graham PhD, Administrator, Office of Management and Budget, Executive Office of the President, Washington, DC, USA, who discussed risk management and encouraged ISPOR members to be more involved in risk management, and Janet Woodcock MD, Director, Center for Drug Evaluation & Research, Rockville, MD, USA, discussed whether recent trends in the withdrawal of drugs from the market highlight a new era of risk control.
After the second Plenary Session, there was an additional viewing of the Second Poster Session and Exhibits, followed by lunch. The participants then attended the Issues Panels on Is $50,000/QALY High Enough for a US Benchmark? led by A. Mark Fendrick MD, Associate Professor, University of Michigan Medical Center, Ann Arbor, MI, USA; What’s Next for Outcomes Research in Asia?, led by Hong Li PhD, Associate Director, Bristol-Myers Squibb, Wallingford, CT, USA, Medication Compliance: How Can It Be Included in Pharmacoeconomic Studies?, led by Joyce Cramer BS, Associate Research Scientist, Yale University School of Medicine, West Haven, CT, USA, and Using Health Economic and Other Outcomes Information to Develop Sound Prescription Drug Plans: Practical or Improbable in the US?, led by Joanna Siegel ScD, Director, Research Initiative in Clinical Economics, Agency for Healthcare Research & Quality, Rockville, MD, USA.
 

Second Plenary Session: (l-r) Janet Woodcock MD,
John D. Graham PhD, Peter Neumann ScD

After a short break, participants attended Contributed Workshop Presentations
in 4 scientific tracks.
At 4 pm the ISPOR Forums were held. The Medical Devices and Diagnostics Forum, included Using Outcomes Research Studies to Support Improved Productivity, moderated by Pamela Koo, Director, Global Reimbursement Policy Welch Allyn, Inc, with speaker Sean Sullivan PhD, PPh, President & CEO, Institute for Health and Productivity Management, Scottsdale, AZ, USA; and How to Support Reimbursement of Off-Label Use of Medical Devices and Diagnostics: Will Outcomes Research Help?, moderated by Randel Richer RN, MPH, Vice President, Federal Affairs, Reimbursement and Outcomes Planning, Boston Scientific Corporation, Natick, MA USA, and Sarah Wells, Boston Scientific Corporation, Boston, Natick, MA, USA, with speaker Stuart Langbein Esq., Hogan & Hartson L.L.P. Washington, DC, USA. The Quality of Life Forum, Summary Measures Of Population Health Status – WHO Cares?, was moderated by Joyce Cramer, Associate Research Scientist, Yale University School of Medicine, New Haven, CT, USA, with speakers Dean Jamison PhD, Senior Research Fellow, Division of International Epidemiology and Populations Studies, Fogarty International Center, National Institute of Health, Bethesda, MD USA, Edward Sondik PhD, Director, National Center for Health Statistics, Center for Disease Control, Hyattsville, MD, USA, Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA, and Diane Wild MSc, Partner, Oxford Outcomes, Headington, Oxford, UK, with presenter Paul Kind Mphil, Senior Research Fellow, Outcomes Research Group, Centre for Health Economics, University of York, York, UK. The Clinical Practice Forum, Using Cost-Effectiveness & Outcomes Research To Increase A Patient's Access To New Drugs: Case Study In Diabetic Complications was moderated by Pamela Chavis MD, Chair, ISPOR Clinical Practice Special Interest Group, and Associate Professor, Department of Ophthalmology, Medical College of Virginia, Richmond, VA, USA, with speakers A. Mark Fendrick MD, Associate Professor, University of Michigan Medical Center, Ann Arbor, MI, USA, Stephen Schwartz MD, Assistant Professor, Department of Ophthalmology, Medical College of Virginia, Richmond, VA, USA, and Matthew Sheetz MD, PhD, Clinical Research Physician, Eli Lilly and Company, Indianapolis, IN, USA.

The ISPOR General Membership Business Meeting followed with the announcement of the new 2002-2003 ISPOR Board members.

Wednesday, May 22, 2002
The last day of the meeting began with Breakfast with the Experts, with discussions on Cost-Effectiveness Analysis in the Developing World, led by Joan Rovira PhD, Health, Nutrition and Population, The World Bank, Washington, DC, USA; Pharmaceutical Costs, Expenditures and Policy Implications, led by C. Daniel Mullins PhD, Associate Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA; and Issues in Modeling in Cost-Effectiveness, led by J. Jaime Caro MD, Scientific Director, Caro Research, Concord, MA, USA; Economic Evaluation Alongside Clinical Trials, led by Henry Glick PhD, Health Economist, Division of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
 

Third Plenary Session:
(l-r) Charles Inlander, Newell E. McElwee PharmD, MSPH,
Karen Donelan ScD, Eva Lydick PhD, Linda Golodner

The Third Plenary Session titled The Rise of Consumerism, revealed how the evolution of managed care has given rise to the consumer as the most powerful entity in the setting of coverage priorities, as well as how increased emphasis on direct-to-consumer (DTC) promotion and the Internet’s disintermediation, consumers have become more knowledgeable and more opinionated about the treatments they want covered. The session was moderated by Eva Lydich PhD, 2001-2002 ISPOR President. Speakers were Linda F. Golodner, Executive Director, National Consumer League, Washington, DC, USA; Charles Inlander, President, People’s Medical Society, Fogelsville, PA, USA, and Karen Donelan ScD, Senior Vice President, Medrock, Cambridge, MA, USA. Newell McElwee PharmD, MSPH, Senior Director/ Team Leader, Global Outcomes Research, Pfizer, Inc, New York, NY, USA, was also on the panel as a discussant. n

We look forward to seeing you at the ISPOR 5th Annual European Congress, in Rotterdam, Netherlands, 3-5, November 2002!


  Issues Index | 2002 Issues Index